EGRX

Eagle Pharmaceuticals, Inc.

Delisted

EGRX was delisted on the 2nd of October, 2024.

174 hedge funds and large institutions have $832M invested in Eagle Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 62 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding in top 10

Funds holding in top 10:

more call options, than puts

Call options by funds: $ | Put options by funds: $

more funds holding

Funds holding:

2% less capital invested

Capital invested by funds: $853M → $832M (-$20.7M)

11% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 62

Holders
174
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$7.07M
Puts
$6.34M
Net Calls
Net Calls Change

Top Buyers

1 +$15.6M
2 +$12.9M
3 +$6.6M
4
CEI
Clark Estates Inc
New York
+$2.96M
5
GC
Guggenheim Capital
Illinois
+$2.87M
Name Holding Trade Value Shares
Change
Change in
Stake
76
$642K
77
$632K
78
$595K
79
$581K
80
$579K
81
$561K
82
$524K
83
$522K
84
$481K
85
$481K
86
$473K
87
$460K
88
$454K
89
$452K
90
$440K
91
$438K
92
$433K
93
$430K
94
$427K
95
$421K
96
$411K
97
$357K
98
$357K
99
$348K
100
$340K